Date: 2014-12-15
Type of information: Nomination
Compound: member of the board of directors
Company: Silence Therapeutics (UK)
Therapeutic area: Cancer - Oncology - Metabolic diseases - Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 15, 2014, Silence Therapeutics announced that the company has appointed Dr Lars Karlsson as Head of Research and Development from 5 January 2015. He will also join the board as an executive director. A medical doctor by training, Lars has over 20 years’ experience in research and development within the pharmaceutical and biotech industries. He joins Silence from Novo Nordisk where he was the Vice President for Auto-Immune Disease Pharmacology, responsible for all inflammatory research within Denmark. He was previously Head of Translational Immunology at Norvo Nordisk where he built up a translational research unit focused on disease
relevance and adequate dosing of new compounds entering clinical trials. Prior to this, Lars was also Vice President of Immunology and Fibrosis at micro RNA therapeutics company, Regulus Therapeutics, where he was operationally responsible for research alliances with Sanofi and with GSK. He also spent 11 years working for Johnson & Johnson.
Financial terms:
Latest news:
Is general: Yes
